Related Experiment Video
Updated: Apr 28, 2026
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Prostate cancer relevant antigens and enzymes for targeted drug delivery
Ashutosh Barve1, Wei Jin1, Kun Cheng1
1Division of Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, Kansas City 64108, USA.
Abstract:
Chemotherapy is one of the most widely used approaches in combating advanced prostate cancer, but its therapeutic efficacy is usually insufficient due to poor specificity and associated toxicity. Lack of targeted delivery to prostate cancer cells is also the primary obstacles in achieving feasible therapeutic effect of other promising agents including peptide, protein, and nucleic acid. Consequently, there remains a critical need for strategies to increase the selectivity of anti-prostate cancer agents. This review will focus on various prostate cancer-relevant antigens and enzymes that could be exploited for prostate cancer targeted drug delivery. Among various targeting strategies, active targeting is the most advanced approach to specifically deliver drugs to their designated cancer cells. In this approach, drug carriers are modified with targeting ligands that can specifically bind to prostate cancer-specific antigens. Moreover, there are several specific enzymes in the tumor microenvironment of prostate cancer that can be exploited for stimulus-responsive drug delivery systems. These systems can specifically release the active drug in the tumor microenvironment of prostate cancer, leading to enhanced tumor penetration efficiency.
Insights
Targeted drug delivery enhances prostate cancer treatment by exploiting cancer-specific antigens and enzymes. This approach improves drug selectivity and reduces toxicity for better therapeutic outcomes.
Area of Science:
- Oncology
- Drug Delivery
- Biochemistry
Background:
- Chemotherapy for advanced prostate cancer has limited efficacy due to poor specificity and toxicity.
- Targeted delivery of novel agents like peptides, proteins, and nucleic acids to prostate cancer cells remains a challenge.
- There is a critical need for strategies to enhance the selectivity of anti-prostate cancer agents.
Purpose of the Study:
- To review prostate cancer-relevant antigens and enzymes for targeted drug delivery.
- To explore active targeting strategies using ligands for prostate cancer-specific antigens.
- To discuss stimulus-responsive drug delivery systems utilizing tumor microenvironment enzymes.
Main Methods:
- Review of literature on prostate cancer antigens and enzymes.
- Analysis of active targeting strategies involving ligand-modified drug carriers.
- Examination of stimulus-responsive systems for enzyme-triggered drug release.
Main Results:
- Prostate cancer-specific antigens can be targeted using modified drug carriers with specific ligands.
- Enzymes within the prostate cancer tumor microenvironment can be leveraged for stimulus-responsive drug release.
- Targeted delivery and stimulus-responsive systems show potential for enhanced drug selectivity and tumor penetration.
Conclusions:
- Exploiting prostate cancer antigens and enzymes offers promising strategies for targeted drug delivery.
- Active targeting and stimulus-responsive systems can overcome limitations of conventional chemotherapy.
- These advanced approaches aim to improve therapeutic efficacy and reduce side effects in prostate cancer treatment.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
01:24Modified-Release Drug Delivery Systems: Site-Targeted